Search Results

There are 3633 results for: content related to: FDA contributions to reduction of bacterial contamination in platelet products within the United States

  1. Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis

    Catheterization and Cardiovascular Interventions

    Volume 69, Issue 7, 1 June 2007, Pages: 1064–1074, Tina L. Pinto Slottow and Ron Waksman

    Article first published online : 24 MAY 2007, DOI: 10.1002/ccd.21179

  2. FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations

    Journal of Interventional Cardiology


    Article first published online : 27 NOV 2007, DOI: 10.1111/j.1540-8183.2007.00312.x

  3. You have full text access to this OnlineOpen article
    An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease

    British Journal of Clinical Pharmacology

    Volume 62, Issue 2, August 2006, Pages: 138–152, Mark A. Giembycz

    Article first published online : 2 MAR 2006, DOI: 10.1111/j.1365-2125.2006.02640.x

  4. You have free access to this content
    Perspectives on FDA's Regulation of Nanotechnology: Emerging Challenges and Potential Solutions

    Comprehensive Reviews in Food Science and Food Safety

    Volume 8, Issue 4, October 2009, Pages: 375–393, Brianna (MacDonald) Sandoval

    Article first published online : 16 SEP 2009, DOI: 10.1111/j.1541-4337.2009.00088.x

  5. The mantra of blood safety: time for a new tune?

    Vox Sanguinis

    Volume 86, Issue 1, January 2004, Pages: 1–7, A. Farrugia

    Article first published online : 30 JAN 2004, DOI: 10.1111/j.0042-9007.2004.00386.x

  6. Race Categorization and the Regulation of Business and Science

    Law & Society Review

    Volume 44, Issue 3-4, September/December 2010, Pages: 617–650, Catherine Lee and John D. Skrentny

    Article first published online : 18 OCT 2010, DOI: 10.1111/j.1540-5893.2010.00418.x

  7. Brief report on the United States Food and Drug Administration Blood Products Advisory Committee recommendations for management of donors and units testing positive for hepatitis B virus DNA

    Vox Sanguinis

    Volume 91, Issue 4, November 2006, Pages: 331–335, C. Lucey

    Article first published online : 18 JUL 2006, DOI: 10.1111/j.1423-0410.2006.00820.x

  8. You have free access to this content
    A systematic review of the safety of topical therapies for atopic dermatitis

    British Journal of Dermatology

    Volume 156, Issue 2, February 2007, Pages: 203–221, J. Callen, S. Chamlin, L.F. Eichenfield, C. Ellis, M. Girardi, M. Goldfarb, J. Hanifin, P. Lee, D. Margolis, A.S. Paller, D. Piacquadio, W. Peterson, K. Kaulback, M. Fennerty and B.U. Wintroub

    Article first published online : 29 SEP 2006, DOI: 10.1111/j.1365-2133.2006.07538.x

  9. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world

    Annals of the New York Academy of Sciences

    Volume 1241, Issue 1, December 2011, Pages: 153–161, Roger M. Echols

    Article first published online : 22 DEC 2011, DOI: 10.1111/j.1749-6632.2011.06300.x

  10. You have free access to this content
    Steering a course for risk assessment: The impact of new draft guidance, 21 CFR part 11, scope and application, on the electronic records; electronic signatures rule

    The Quality Assurance Journal

    Volume 7, Issue 3, September 2003, Pages: 182–186, George G. Kuniholm

    Article first published online : 29 JUL 2003, DOI: 10.1002/qaj.237

  11. Variant Creutzfeldt–Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty

    Vox Sanguinis

    Volume 89, Issue 4, November 2005, Pages: 186–192, A. Farrugia, J. W. Ironside and P. Giangrande

    Article first published online : 12 OCT 2005, DOI: 10.1111/j.1423-0410.2005.00702.x

  12. Collaborative study to establish a replacement World Health Organization International Standard for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays

    Vox Sanguinis

    Volume 98, Issue 3p2, April 2010, Pages: 441–446, S. A. Baylis, M. Chudy, J. Blümel, G. Pisani, D. Candotti, M. José and A. B. Heath

    Article first published online : 8 DEC 2009, DOI: 10.1111/j.1423-0410.2009.01288.x

  13. Analysis of progression-free survival in oncology trials: some common statistical issues

    Pharmaceutical Statistics

    Volume 6, Issue 2, April/June 2007, Pages: 99–113, Kevin J. Carroll

    Article first published online : 22 JAN 2007, DOI: 10.1002/pst.251

  14. Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 7, July 2007, Pages: 762–772, Li-Chia Chen and Darren M Ashcroft

    Article first published online : 25 APR 2007, DOI: 10.1002/pds.1409

  15. You have full text access to this OnlineOpen article
    The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors

    Arthritis Care & Research

    Volume 47, Issue 4, 15 August 2002, Pages: 349–355, Vibeke Strand and Marc C. Hochberg

    Article first published online : 12 AUG 2002, DOI: 10.1002/art.10560

  16. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials

    Journal of Clinical Pharmacy and Therapeutics

    Volume 31, Issue 6, December 2006, Pages: 565–576, L-C. Chen and D. M. Ashcroft

    Article first published online : 24 NOV 2006, DOI: 10.1111/j.1365-2710.2006.00774.x

  17. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions

    Pharmacoepidemiology and Drug Safety

    Volume 19, Issue 2, February 2010, Pages: 158–174, Carol A. Pamer, Tarek A. Hammad, Yu-te Wu, Sigal Kaplan, George Rochester, Laura Governale and Andrew D. Mosholder

    Article first published online : 4 JAN 2010, DOI: 10.1002/pds.1886

  18. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience

    Pharmacoepidemiology and Drug Safety

    Volume 15, Issue 4, April 2006, Pages: 213–220, Lawrence Goldkind and Loren Laine

    Article first published online : 3 FEB 2006, DOI: 10.1002/pds.1207

  19. Current issues in non-inferiority trials

    Statistics in Medicine

    Volume 27, Issue 3, 10 February 2008, Pages: 317–332, Thomas R. Fleming

    Article first published online : 5 MAR 2007, DOI: 10.1002/sim.2855

  20. You have full text access to this OnlineOpen article
    A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme

    Alimentary Pharmacology & Therapeutics

    Volume 24, Issue 5, September 2006, Pages: 869–878, D. MILLER, L. BENNETT, K. HOLLIS, P. TENNIS, S. COOK and E. ANDREWS

    Article first published online : 16 AUG 2006, DOI: 10.1111/j.1365-2036.2006.03031.x